MINDCURE Announces Manufacturing of Synthetic Ibogaine to be Used in Company's Clinical Research
Share: The Company expects to have ibogaine manufactured and in use for research by Q4. VANCOUVER, BC, March 3, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE:MCUR) (OTCQB:MCURF) (FRA: 6MH) ( "MINDCURE" or the "Company") a leader in advanced proprietary technology for psychedelic drug discovery, is pleased to announce that it has begun the first stage of manufacturing pharmaceutical grade ibogaine to be used in preclinical and clinical research. Ibogaine is a naturally occurring psychoactive compound extracted from the root of the Tabernanthe iboga shrub , native of the Congo and Gabon. 1 ...